By the same token, there are several first-line options available for treating EGFRM+ NSCLC (i.e., 1G, 2G, and 3G TKIs, TKI+antiangiogenic agent and TKI+chemotherapy) after the report of the remarkable PFS benefit and immature OS data for osimertinib vs. 1G EGFR-TKIs and of the ARCHER phase III study displaying the superior PFS and OS benefit of the 2G TKI dacomitinib vs. 1G TKI [24,295,296]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.